SSSean Stuart

Sean Stuart

*This is an algorithmically generated author record based on publicly available information.

Sean Stuart has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Stewarding waste and antimicrobials: an assessment of chorioamnionitis regimens

    by Pamela Bailey, Alexia Foy-Crowder, Joseph Kohn, Benjamin Ereshefsky, Amber Shaye Beville, Sean Stuart, Amy Crockett

    Stewardship is not only about appropriate antibiotic prescribing, but also improving the utilization of resources. While multiple treatment regimens are endorsed for chorioamnionitis, some produce significantly more plastic waste than others. Ampicillin with gentamicin ± clindamycin, and vancomycin with gentamicin both create more plastic waste compared to regimens like cefoxitin, piperacillin/tazobactam, or ertapenem.

  • Open Access

    Stewardship opportunities in peripartum infections: a review of quality improvement initiatives and future directions

    by Pamela Bailey, Grace Pazienza, Alexia Foy-Crowder, Lance Schacht, Mattie Jo Thomas, Joseph Kohn, Sarah Withers, Jessica Britt, Sean Stuart, Amy Crockett

    Antimicrobial resistance is an urgent public health threat, and despite significant consumption of antimicrobials in pregnancy, there remain opportunities for improvement of their use in the obstetric population. Improvement in antimicrobial utilization can be streamlined by assessing baseline characteristics, utilization of diagnostic testing, awareness of peripartum protocols, and recognition of penicillin allergies. In a single healthcare system including 8 obstetric hospitals, an administrative review identified 199 different regimens used among 8,528 patients based on American College of Obstetrician and Gynecologists (ACOG) guidelines. Other notable factors include 65.6% of patients having no cultures obtained despite being started on empiric antibiotics, duplicative coverage when multiple clinical scenarios overlap, and a high incidence of reported penicillin allergies with obstetric providers lacking comfort to reconcile and de-label allergies. By reviewing these individual aspects, this can highlight opportunities for improvement of antimicrobial use and stewardship in obstetric populations.


  • Open Access

    Intrauterine vacuum-induced hemorrhage-control device for hemorrhage after myomectomy: a case report and review of the literature

    by David Lee, Sean Stuart, Ylbe Franco-Marx

    Background: The Jada intrauterine vacuum-induced hemorrhage-control device was approved by the United States Food and Drug Administration (FDA) in 2020 and serves as an additional instrument for controlling postpartum hemorrhage. The device utilizes low-level vacuum to induce myometrial contraction, thereby rapidly controlling hemorrhage. The utility of the device for management of postpartum hemorrhage is well-described. However, its use for intraoperative hemorrhage in gynecologic surgery has not yet been reported. Case Description: We present the experience of a 39-year-old patient who presented for heavy vaginal bleeding and a mass protruding from her vagina. Examination in the emergency room (ER) was consistent with a large prolapsing necrotic myoma. She underwent an emergent exam under anesthesia and vaginal myomectomy, after which brisk bleeding was noted from the uterus. Her bleeding was refractory to bimanual massage. An intrauterine vacuum-induced hemorrhage-control device was inserted and bleeding rapidly resolved. The device was removed on post-operative day (POD) #1 and minimal bleeding was noted through the remainder of her post-operative course. The device was successful in treatment of intraoperative hemorrhage after vaginal myomectomy. Application was identical to application for postpartum hemorrhage and the effect was rapid. Conclusions: The Jada was successfully applied in an acute episode of heavy bleeding during management of abnormal uterine bleeding secondary to a large prolapsing necrotic myoma. It may be of interest to formally pursue studies investigating future applications of Jada in controlling other etiologies of abnormal uterine bleeding in gynecologic surgery.